Obesity, unspecified Vitamin D
Conditions
Interventions
This is a randomized, double-blind, controlled clinical trial with two arms. In the experimental group, twelve women with obesity and twelve women with normal BMI will receive cholecalciferol 2,000 IU
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Women with obesity (BMI greater than or equal to 30 kg/m²), aged 18 to 60 years, followed at the Obesity Outpatient Clinic. Control group: women with BMI between 18.5 and 24.9 kg/m², aged 18 to 60 years
Exclusion criteria
Exclusion criteria: Age under 18 years; pregnancy or lactation; intestinal malabsorptive disorders; use of medications that interfere with vitamin D metabolism or absorption (corticosteroids, anticonvulsants, isoniazid, antiretrovirals, antifungals, orlistat, cholestyramine); primary/tertiary hyperparathyroidism; hypoparathyroidism; osteoporosis; osteomalacia; rickets; thyrotoxicosis; chronic kidney disease (creatinine clearance under 45 mL/min); history of cancer; chronic liver failure; patient refusal. Use of any commercial vitamin D formulations within the past 2 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A greater and earlier increase in serum 25-hydroxyvitamin D levels is expected in the group receiving calcifediol compared to the groups receiving cholecalciferol or placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that a greater decline in serum 25-hydroxyvitamin D levels will be observed 30 days after discontinuation of the capsules in the group that received calcifediol for 90 days, compared to the group that received cholecalciferol for 90 days | — |
Countries
BR
Contacts
Public ContactWesdrey Fernandes
Universidade Federal de São Paulo
Outcome results
None listed